In the European Region, measles elimination is now targeted to 2015. To measure progress towards elimination age-group specific susceptibility targets have been defined. Age-specific measles susceptibility in children and adolescents was evaluated in Germany. Taking into account a broad range of socio-demographic, health-and vaccination status related variables, populations for vaccination campaigns were identified.
Sero-epidemiology of measles-specific IgG antibodies and predictive factors for low or missing titres in a German population-based cross-sectional study in children and adolescents (KiGGS)

Background and objective:
In the European Region, measles elimination is now targeted to 2015. To measure progress towards elimination age-group specific susceptibility targets have been defined. Age-specific measles susceptibility in children and adolescents was evaluated in Germany. Taking into account a broad range of socio-demographic, health-and vaccination status related variables, populations for vaccination campaigns were identified.
Method
We analysed data from children aged 1 to 17 years in the representative German Health Interview and Examination Survey for Children and Adolescents (KiGGS). Measles immunoglobulin G antibodies were measured in 13,977 participants by enzyme immunoassay (ELISA). Bivariate and multivariate logistic regression analyses were used to determine parental and infant related factors associated with measles susceptibility.
Results
The overall prevalence of seronegativity in children tested for measles IgG aged 1 to 17 years was 10.0% (95% CI 9.4-10.7). The prevalence of seronegativity in the German population was below the WHO targets for measles elimination in children aged 2 to 9 year-olds but exceeded the target for 10 to 17 year-olds. Age differences in the level of seronegativity were found to be mainly due to differences in vaccination coverage. A higher level of susceptibility was observed if parents did not comply with the request to present the child's vaccination card. In vaccinated children, immigration, male gender, very young age at first vaccination and a longer time period since last vaccination were associated with a higher level of susceptibility.
Conclusion
Further increase of the two-dose vaccination coverage is necessary in order to achieve the WHO targets. Catch up vaccination campaigns should focus on adolescents and immigrants.
Introduction 38
Measles, elimination goal:
39
Despite worldwide vaccination activities, measles is still a major cause of death especially in 
142
Focus of infection reduction neutralisation test (FRNT).
143
Compared to the ELISA measuring all classes of IgG able to bind to the respective antigen, known to be more sensitive than ELISA. Recently FRNT was shown to be a good substitute 147 for PRNT for characterising the immune response to mumps and for vaccine efficacy studies 148 (12). Although the FRNT is less laborious than the PRNT, it cannot be used for large numbers 149 of samples. Thus, the FRNT was used to characterise only the sera of patients tested negative 150 in ELISA after vaccination in order to determine whether they had neutralising antibodies.
151
The FRNT was performed as follows: Vero-SLAM cells were seeded in 48 well plates and 152 incubated for 48 h. Serum samples were inactivated for 30 min at 56°C and serially diluted.
153
Edmonston Zagreb (30 pfu in 50 µl) was incubated for 1 h at 37°C. Cells were inoculated 154 with 100 µl of the serum/virus mixture for 1h at 37°C in a CO 2 incubator and covered with a 155 500 µl overlay of 1% carboxymethylcellulose (CMC). Cells were incubated for 5 d at 37°C 156 and 5% CO 2 . For fixation, cells were washed with cold Phosphate buffered saline (PBS) and 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 
175
The overall prevalence of seronegativity in children tested for measles IgG aged 1 to 17 years 176 was 10.0% (95% CI 9.4-10.7). In addition, 2.3% (95% CI 2.0-2.7) of children displayed an 177 equivocal titre. In 2-4 year old children, the prevalence of seronegativity was, on average, 178 10.0% (95% CI 8.7-11.6). Each age stratum within this age group met the WHO target for 179 seronegativity (<15%). The prevalence of seronegativity in 5-9 year old children was, on 180 average, 8.4% (95% CI 7.4-9.5). Also in this group each age stratum was below the respective 181 WHO target for seronegativity (<10%). The prevalence of seronegativity in 10-17 year old 182 children and adolescents was, on average, 8.3% (95% CI 7.6-9.1). In contrast to the younger 183 age groups, each age stratum missed the WHO target for 10 to 19 year olds of 5%. The overall 184 prevalence of an equivocal titre level in children aged 1 to 17 years was 2.3% (95% CI 2.0-185 2.7). Low titres in vaccinated persons can be a consequence of waning immunity (secondary 186 vaccine failure) or insufficient response to the vaccine (primary vaccine failure). Prevalence of 187 equivocal titres was higher in older children: in 2 to 4 year olds, only 0.8% (95% CI 0.5-1.4) 188 had equivocal titres, whereas in 5 to 9 year olds and in 10 to 17 year olds, the proportion was 189 1.65% (95% CI 1.3-2.1) and 3.3% (95% CI 2.8-3.9), respectively. provided (or for whom parents reported that they were (yet) unvaccinated) in comparison to 194 children for whom parents did not present a vaccination card at the study centre or for whom 195 the vaccination card was reported to be incomplete. However, clear differences were detected by age (Table 1) presented or for whom it was reported that they were (yet) unvaccinated.
225
The overall prevalence of seronegativity in children aged 1 to 17 years was 9.5% (95% CI 226 8.9-10.2); 2.3% (95% CI 2.0-2.6) of children displayed an equivocal titre level. The 227 proportion of seronegative children differed by age and was highest in children aged 1 year 228 (39.2%; 95% CI 34.2-44.5) and lowest in children aged 5 to 17 years (7.7%). The proportion 229 of children with equivocal titre level was higher in children older than 10 years than in 230 younger children. Differences in seronegativity were also seen by gender and place of lower in children with migration background who were born in Germany (8.2%; 95% CI 6.9-236 9.8) and in children without a migration background (9.5%; 95% CI 8.9-10.3). Also the 237 proportion of children with equivocal antibody levels was higher among immigrants. Antibody levels were also more often equivocal in children who had received their first 258 vaccination at an early age. We observed a linear association between age up to the 17 months 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 
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In the whole study population, seronegativity was slightly lower in children for whom parents 264 reported a history of measles (8.0%; 95% CI 6.1-10.4) in comparison to children without a 265 reported history of measles (9.9%; 95% CI 9.2-10.6). However, significant differences were (1:20-1:274). In 27 of them antibodies were only detectable if dilution was below 1:120.
280
We also re-analysed 20 sera from children who had received their first vaccination before the 281 age of one year and had received at least two doses of measles vaccine, with the last dose less 282 than three years before the study. These 20 children had IgG measles antibody titres between 283 4 and 144 mIU/ml in the ELISA test. Also in this group measles antibodies were detectable by 284 FRNT in all but one child if dilution did not exceed 1:120.
285
As a control, 25 sera of unvaccinated children aged below 7 years who had an IgG measles 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 11 modifying the odds of a negative antibody titre after vaccination (Table 3) . These analyses 295 included 12,161 vaccinated children whose blood sample was taken at least 21 days after their 296 first vaccination.
297
In addition to the variable of parental reported measles infection, factors that were tested 298 statistically significant in the univariate analysis were included in the multivariate analysis.
299
The analysis stratified for single dose or two-dose vaccination schedules indicated that 300 seronegativity was associated with the number of years that had passed since last vaccination:
301
Children who had received their last vaccination more three to six years before the study had a 302 two-to three-fold odds of being seronegative in comparison to children who had received the 303 last (of at least two) vaccination no more than two years before the study (OR 1.95; 95% CI 304 1.37-2.77). Children who had received their last vaccination more than six years before the 305 study had a three-fold odds of being seronegative in comparison to children who had received 306 their last vaccination no more than two years before the study (OR 3.67; 95% CI 2.37-5.69).
307
Seronegativity was more likely in children who had received the first measles vaccination 308 during their first year of life than in children who had received the first dose after the first year 309 of life. The odds of being seronegative after early vaccination was 2.86 (95% CI 1.64-3.19) 310 for a single dose and was 2.29 (95% CI 1.64-3.19) for two-dose vaccination.
311
Seronegativity was more likely in children below the age of 2 years (OR 2.38; 95% CI 1.31- 
318
In this group of vaccinated children, children whose parents reported a history of measles 319 were no more likely to be seronegative than children whose parents had not reported a history 
Discussion
325
Main results
326
The prevalence of seronegativity found in our study was below the WHO European Region 327 targets (1) for measles elimination of <15% in children aged 2 to 4 years and <10% in 5 to 9 328 year-olds. However, the prevalence of seronegativity in 10 to 17 year-olds seen in our study,
329
exceeded the WHO European Region target of <5%. The proportion of seronegative children 330 was particularly high in the youngest children (one year of age), indicating a relevant delay of 331 the first measles vaccination which is scheduled in Germany at the age of 11 to 14 months.
332
Seronegativity was lower in children for whom a vaccination card was available compared to 333 those for whom no vaccination card was provided.
334
Seronegativity was highest in unvaccinated children and was (slightly) above the overall 335 WHO target level of 5% in children who had received a single dose vaccination. 
346
Multivariate analyses showed a three-fold odds of seronegativity in children whose last 347 vaccination had been more than six years before this study. It is remarkable that even in 348 children who received a second vaccination after the first year of life, an early first vaccination 349 was associated with a higher risk of seronegativity. 
Strengths and Limitations
352
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441
Our study shows that young age at first vaccination is associated with a higher probability of 442 seronegativity, even in children that were revaccinated at an older age (Table 3, Figure 3 ).
443
These results indicate that mispriming of the immune system after early vaccination cannot be 444 cured by a late second dose of MCV. This finding is alarming, but must be weighed against 
Conclusions
501
The prevalence of seronegativity in the German population was below the WHO targets for 502 measles elimination in children aged 2 to 9 year-olds but exceeded the target for 10 to 17 year-503 olds. Age differences in the level of seronegativity were found to be mainly due to differences Our large, representative study showed inferior immune responses in children who were very 509 young age at first vaccination (even if a second vaccination was given at older age). Children 510 who received their first vaccination within the first 12 months of life exceeded the target of 511 less than 5% seronegativity even if they had a second dose at older ages. We also observed 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 18 waning of antibodies with increasing time since the last vaccination. The prevalence of 513 seronegativity exceeded the WHO target of less than 5% in those children whose last 514 vaccination dose (single dose or two-dose vaccination) was older than six years.
515
The protective effect of measles antibodies below the cut-off of 150 mIU/ml in vaccinated 516 subjects needs to be investigated further.
517
Our results may contribute to discussions about future adaptations to the current vaccination 518 schedules. Protecting the majority of children at an early age by scheduling the first 519 vaccination within the first year of life has to be traded off against the lower prevalence of 520 seropositivity, especially as failure of the first vaccination cannot be compensated by a second 521 vaccination in a significant proportion of children. This risk assessment will be highly 522 influenced by the measles incidence of a given region. Since measles incidence is still high in 1.
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